TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Ireland > Top Tips to Avoid the Frequent FDA Form 483 Observations

Top Tips to Avoid the Frequent FDA Form 483 Observations

FDA Observations: While the regulations haven’t changed dramatically in recent years, the compliance expectation is ever increasing. The inspectorate’s use of computerised systems (e.g., Turbo EIR) allow inspectors to focus on industry trends and take a more risk-based approach. This leads inspectors towards common noncompliance areas within industry quality systems. As an industry, we need to be prepared for FDA’s increased focus on these trouble areas and focusing on these is a good starting point for risk reduction. One way to approach this is to address the governing quality systems that cover the top hitting observations. Monitoring the status of your site’s quality systems and reacting to reported quality metrics helps to avoid compliance issues and facilitates continuous improvements.

  1. Procedures not in writing or not fully followed (21 CFR 211.22(d))

For a pharmaceutical company to prove to the FDA that it is operating within the highest standard of compliance, its standard operating procedures (SOPs) must be clearly written, and maintained and modified in a timely and consistent manner. Pharma companies can experience difficulty in this area when their document control systems are paper-based, dispersed between a number of locations, or if the company does not sufficiently track approvals and signatures. SOPs can be complex to create and maintain. However, regulatory bodies are becoming more and more focused on compliance and enforcement operations. Most SOPs are very complex and can be difficult to read and follow on a daily basis. Too much information and excessive detail increases the risk of errors and mistakes. Complexity leads to greater risk of error, demotivation and disengagement amongst personnel. How to avoid the observations: Restructuring SOPs can seem expensive and complicated. Simplify complex or confusing SOPs to help avoid a “procedures not fully followed” observation. Re-engineering your procedures, red line the procedure in the field, maintain simplicity, use photos / drawings to clarify, reduce the number of people involved in the tasks, test and verify SOP function. An electronic system is key to automating the routing and delivery of SOPs, policies, work instructions, and other pertinent documentation to designated personnel while maintaining SOPs and other critical documentation in a secure, web-based repository.

  1. Discrepancies and/or failures in investigations (21 CFR 211.192)

The trend shows that deviations handling, investigations and CAPA are recurring through pharma, device, and biologics. All deviations from written procedures must be thoroughly investigated, according to the 21 CFR 211.192 guideline, and the results of those investigations must be adequately documented. In 2016, Investigations of discrepancies in Production record review (CFR 211.192) continued to be one of the most frequently cited observations for drug products by the FDA. If a pharmaceutical company is unable to identify potential root causes and make sufficient record of them, their internal investigations will be viewed by the FDA as incomplete. How to avoid these types of Observational Warnings: At minimum, a good closed loop investigation system is comprised of the following elements Identification, Prioritisation, Assignment/Acknowledgement, Investigation, Correction, Implementation, Verification and Close. Following on from the investigation element, often companies will come to a root cause. For example: equipment failure/ availability/design or procedure inadequate or procedure not followed or human error. While these are valid intermediate root causes, they need further analysis to arrive at a truly effective CAPAs. At this point it is important to add another layer to the root cause investigation to establish the true root cause. The investigation into and documentation of quality events is drastically simplified with Quality Management software that enables an organization to automate the management of the entire CAPA process, from initiation to investigation and all the way through to closure.         3.Process Equipment, subsection 5.4 Computerised Systems, paragraph 5.43 of guideline ICH Q7 which states: “Computerised systems should have sufficient controls to prevent unauthorised access or changes to data. There should be controls to prevent omissions in data (e.g. system turned off and data not captured). There should be a record of any data change made, the previous entry, who made the change, and when the change was made.” Typical examples referred to the unregulated access to raw electronic data as follows:

  • deleting of “bad” analyses (HPLC) after choosing the ones with specification compliant results
  • manipulation of metadata in audit trail
  • changing the date of analyses

 How to avoid these types of Observational Warnings: As part of your company’s internal audit procedure, data integrity should be systematically checked across all key GMP functions. The scope should cover items such as

  • How is access authorised and controlled?
  • Have you justified access levels and the user privileges at each level?
  • Are there specific user profiles to access software and provide audit trails for traceability?
  • Is there restricted privileges (can’t delete/ write-over / move)?
  • Is the administration independent of the analytical function?
  • How is it enforced that passwords are not shared?
  • Are passwords changed periodically and are they of high strength?
  • Is the Audit Trail functionality switched on?
  • Is the Date/ time functionality locked by IT?
  • Has the system been validated for its intended use?
  • Are all data processing methods validated and locked by the administrator?
  • Is it necessary to ‘save’ before it is submitted for review?
  • Are accurate audit trail entries put in when prompted?

If you would like PharmaLex Ireland – a PharmaLex Company to  assist your organisation , please contact us at +353 1 846 47 42 or contactirl@pharmalex.com.

Related posts
Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic
Resilience of Pharma Supply Chains and the Impact of Covid-19 Pandemic
17th May 2021
Contamination Control
Contamination Control
8th April 2021
Rules on Ownership of Medicinal Product stock distributed in Great Britain
Rules on Ownership of Medicinal Product stock distributed in Great Britain
7th April 2021
GET SMART: reliable analytical results & continuous regulatory compliance!
GET SMART: reliable analytical results & continuous regulatory compliance!
30th March 2021
Challenges of Advanced Therapy Medicinal Products (ATMPs)
Challenges of Advanced Therapy Medicinal Products (ATMPs)
16th March 2021
Supporting M&A in the pharmaceutical / biopharmaceutical industry
Supporting M&A in the pharmaceutical / biopharmaceutical industry
11th February 2021
Search
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Categories
  • All News
  • Webinars
  • Events
Archive
Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Able to explain technical details so non-experts can understand

    US based small / virtual company
    Partner
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for